Glucose-6-phosphate dehydrogenase (G6PD) deficiency is an inherited disorder caused by a genetic defect in the red blood cell (RBC) enzyme G6PD, which generates NADPH and protects RBCs from oxidative injury. G6PD deficiency is the most common enzymatic disorder of RBCs. The severity of hemolytic anemia varies among individuals with G6PD deficiency, making diagnosis more challenging in some cases. Identification of G6PD deficiency and patient education regarding safe and unsafe medications and foods is critical to preventing future episodes of hemolysis. The most common medical problem associated with G6PD is hemolytic anemia, which occurs when red blood cells are destroyed faster than the body can replace them. This type of anemia leads to paleness, yellowing of the skin and whites of the eyes (jaundice), dark urine, fatigue, shortness of breath, and a rapid heart rate. In people with G6PD, hemolytic anemia is most often triggered by bacterial or viral infections or by certain drugs (such as some antibiotics and medications used to treat malaria). Hemolytic anemia can also occur after eating fava beans or inhaling pollen from fava plants (a reaction called favism). Both HCQ and vitamin C are contraindicated in patients who have G6PD deficiency. Giving HCQ to a COVID patient with known G6PD would not be advised. If there is a mechanism with COVID already affecting RBCs that affects heme's ability to bind oxygen, giving these patients the proposed COVID protocol could increase poorer outcomes in these patients. http://www.cych.org.tw/pharm/MIMS%20Summary%20Table-G6PD.pdf